etoposide has been researched along with Multiple Myeloma in 186 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (4.30) | 18.7374 |
| 1990's | 46 (24.73) | 18.2507 |
| 2000's | 89 (47.85) | 29.6817 |
| 2010's | 28 (15.05) | 24.3611 |
| 2020's | 15 (8.06) | 2.80 |
| Authors | Studies |
|---|---|
| Chari, A; Cho, HJ; Dharmarajan, K; Jagannath, S; Moshier, E; Nehlsen, AD; Parekh, S; Richard, S; Richter, J; Sanchez, L; Sindhu, KK | 1 |
| Andoh, S; Hagiwara, S; Hirai, R; Itoi, S; Komuro, M; Mitsui, Y; Miwa, A; Nakamura, M; Sekine, R; Takeshita, M; Tanimura, A; Togano, T | 1 |
| Bashey, A; Brown, S; Holland, HK; Jackson, KC; Morris, LE; Shegda, N; Solh, M; Solomon, SR; Zhang, X | 1 |
| Chari, A; Cho, HJ; Jakubowski, R; Moshier, E; Mouhieddine, TH; Parekh, S; Puliafito, B; Rattu, M; Richard, S; Richter, J; Rodriguez, C; Rossi, A; Sanchez, L; Steinberg, A; Thibaud, S | 1 |
| Bang, SM; Byun, JM; Kim, JS; Kim, K; Koh, Y; Lee, JJ; Min, CK; Yoon, SS | 1 |
| Fei, XM; Lei, F; Lu, WP; Wang, LX; Yu, XQ | 1 |
| Goldschmidt, H; Kauer, J; Kriegsmann, K; Müller-Tidow, C; Ober, M; Raab, MS; Sauer, S; Sester, LS; Weinhold, N | 1 |
| Chen, LJ; Jin, YY; Li, J; Li, JY; Lu, H; Qu, XY; Zhang, R | 1 |
| Bhatt, R; Gohari, P; Podrumar, A; Xiao, S | 1 |
| Baize, TC; Basu, SK; Figg, LR; Hashmi, H; Herzig, RH; Jayswal, R; Krem, MM; Manapuram, S; Monohan, G; Reynolds, SB; Weiss, HL | 1 |
| Fiala, MA; Ghobadi, A; Goldsmith, SR; Schroeder, MA; Stockerl-Goldstein, K; Vij, R; Wang, B; Wildes, TM | 1 |
| Basu, S; De Abrew, K; Djebbari, F; Eyre, TA; Hossain, MI; Jenner, M; Kothari, J; Panitsas, F; Ramasamy, K; Salhan, B; Willan, J | 1 |
| Fan, T; He, P; Liu, H; Wang, M; Wang, X; Zhang, M; Zhang, Y | 1 |
| Chen, M; Chen, W; Jiang, Q; Li, T; Liu, Y; Peng, J; Shi, X; Wu, J; Xi, X; Yu, X; Zhang, S; Zhu, Y | 1 |
| Ainley, L; Chavda, SJ; Cheesman, S; Counsell, N; Horder, J; Kyriakou, C; Lee, L; Mehta, A; Newrick, F; Papanikolaou, X; Popat, R; Rabin, N; Sive, J; Wechalekar, A; Yong, K | 1 |
| Anderson, KC; Badros, A; Beksac, M; Bladé, J; Caers, J; Cavo, M; Dimopoulos, MA; Dispenzieri, A; Einsele, H; Engelhardt, M; Fernández de Larrea, C; Gahrton, G; Gay, F; Hájek, R; Hungria, V; Jurczyszyn, A; Kröger, N; Kyle, RA; Leal da Costa, F; Leleu, X; Lentzsch, S; Mateos, MV; Merlini, G; Mohty, M; Moreau, P; Rasche, L; Reece, D; Richardson, PG; Rosiñol, L; Sezer, O; Sonneveld, P; Usmani, SZ; Van de Donk, NWCJ; Vanderkerken, K; Vesole, DH; Waage, A; Zamagni, E; Zweegman, S | 1 |
| Baker, L; Holder, K; Kanellopoulos, A; Kaparou, M; Kishore, B; Lovell, R; Nikolousis, E; Paneesha, S; Randall, K; Ryan, L; Suhr, J; Xenou, E | 1 |
| Choi, E; Meehan, KR; Tsui, EW | 1 |
| Buadi, FK; Dingli, D; Dispenzieri, A; Fonder, AL; Gertz, MA; Go, RS; Gonsalves, WI; Hayman, SR; Hobbs, M; Hwa, YL; Kapoor, P; Kourelis, T; Kumar, SK; Kyle, RA; Lacy, MQ; Lakshman, A; Leung, N; Lin, Y; Lust, JA; Rajkumar, SV; Russell, SJ; Singh, PP; Warsame, R; Zeldenrust, SR | 1 |
| Pinkhas, D; Toocheck, C | 1 |
| Fukuhara, N; Harigae, H; Hatta, S; Himuro, M; Ichikawa, S; Ichinohasama, R; Kobayashi, M; Nasu, K; Okitsu, Y; Onishi, Y; Ono, K; Ri, M | 1 |
| Bergin, K; Coutsouvelis, J; Fedele, P; Grigoriadis, G; Kalff, A; Low, MSY; Spencer, A; Walker, P; Yuen, HLA | 1 |
| Chen, CI; Cheng, L; Gerrie, AS; Jiang, H; Kukreti, V; Mikhael, JR; Panzarella, T; Reece, D; Stewart, KA; Trieu, Y; Trudel, S | 1 |
| Du, J; Fan, JL; Fu, WJ; Hou, J; Jiang, H; Jin, LN; Li, R; Xi, H; Zeng, TM; Zhang, CY; Zhou, LL | 1 |
| Chen, CI; Chu, CM; Cserti-Gazdewich, C; Jiang, H; Jimenez-Zepeda, VH; Kukreti, V; Masih-Khan, E; Rabea, A; Reece, DE; Tiedemann, R; Trudel, S; Tsang, R | 1 |
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Cavenagh, J; Ingram, W; Quinn, J; Smith, D; Stevens, J; Yong, K | 1 |
| Jang, JH; Jung, CW; Kim, K; Kim, SJ; Kim, WS; Lee, SJ; Park, S | 1 |
| Buck, A; Duell, J; Einsele, H; Knop, S; Maeder, U; Rasche, L; Rosenwald, A; Strifler, S | 1 |
| Akhtari, M; Distler, O; Foratyazdi, M; Owlia, MB | 1 |
| Magen, H; Muchtar, E; Oniashvili, N; Raanani, P; Ram, R; Shpilberg, O; Yeshurun, M | 1 |
| Ford, PA; Grant, SJ; Keck, G; Mick, R | 1 |
| Alsina, M; Baz, RC; Fulp, W; Griffin, PT; Ho, VQ; Nishihori, T; Shain, KH | 1 |
| Abidi, MH; Ayash, L; Bhutani, D; Deol, A; Dyson, G; Jain, T; Kim, S; Lum, LG; Ratanatharathorn, V; Uberti, JP; Veeraputhiran, M | 1 |
| Baster, J; Castillos, JJ; Dadej, A; Gdula-Argasińska, J; Giza, A; Jurczyszyn, A; Skotnicki, AB; Vesole, DH; Walter, Z; Węglarska, D; Zawirska, D | 1 |
| Chen, YB; Fu, WJ; Hou, J; Wang, DX; Xi, H; Yuan, ZG | 1 |
| Davies, FE; Dines, S; Ethell, ME; Jenner, MW; Morgan, GJ; Potter, MN; Saso, RM; Shaw, BE; Srikanth, M; Wu, P | 1 |
| Biron, P; Ghesquières, H; Labidi, SI; Nicolas, EV; Sebban, C | 1 |
| Bacon, P; Blijlevens, N; D'Addio, A; Einsele, H; Maertens, J; McCann, S; Niederwieser, D; Quinn, B; Rabitsch, W; Roosaar, A; Ruutu, T; Schouten, H; Schwenkglenks, M; Stone, R; Vorkurka, S | 1 |
| Andreesen, R; Grassinger, J; Hart, C; Hennemann, B | 1 |
| Kanz, L; Kopp, HG; Vogel, W; Weisel, KC; Yildirim, S | 1 |
| Arpaci, F; Ataergin, S; Kilic, S; Komurcu, S; Kuzhan, O; Ozet, A; Ozturk, B; Ozturk, M | 1 |
| Claxton, D; Fink, LM; Ibrahim, S; Talamo, GP; Tricot, GJ; Zangari, M | 1 |
| Heider, U; Jakob, C; Kaiser, M; Lamottke, B; Mieth, M; Sezer, O; von Metzler, I | 1 |
| Alousi, A; Anderlini, P; Andersson, B; Champlin, R; de Lima, M; Giralt, S; Hosing, C; Jones, R; Kebriaei, P; Khouri, I; Körbling, M; McMannis, J; Nieto, Y; Popat, U; Qazilbash, M; Saliba, R; Shpall, E; Thandi, R; Thomas, S; Wang, M; Weber, D | 1 |
| Gafter-Gvili, A; Magen-Nativ, H; Raanani, P; Ram, R; Shpilberg, O; Yeshurun, M | 1 |
| Batár, P; Kiss, A; Kovácsné Kovács, E; Rejto, L; Reményi, G; Sípos, T; Szarvas, M; Szász, R; Udvardy, M; Váróczy, L | 1 |
| Erikci, AA; Ozturk, A; Sayan, O; Tekgunduz, E | 1 |
| Fujisawa, S; Fujita, H; Hagihara, M; Kanamori, H; Kanda, Y; Matsumoto, K; Minami, J; Nakaseko, C; Nakasone, H; Okamoto, S; Oshima, K; Sakai, R; Shimizu, N; Tachibana, T; Takahashi, S; Tsukada, Y; Ueda, T; Yano, S; Yokota, A | 1 |
| Alessandrino, EP; Barbarano, L; Bernasconi, P; Cafro, AM; Carella, AM; Corso, A; Grillo, G; Lazzarino, M; Mangiacavalli, S; Montalbetti, L; Morra, E; Pascutto, C; Spriano, M; Varettoni, M | 1 |
| Mateos, MV; San-Miguel, JF | 1 |
| Coghill, J; Gabriel, D; Irons, R; Moore, D; Rao, K; Serody, J; Sharf, A; Shea, T; Whitley, J; Wood, WA | 1 |
| Bishop, MR; Bryant, K; Dean, RM; Fowler, DH; Hakim, F; Jamshed, S; Neelapu, SS; Odom, J; Steinberg, SM | 1 |
| Balzer, RJ; Champlin, R; de Lima, M; Giralt, S; Hosing, C; Khouri, I; McMannis, J; Popat, U; Qazilbash, M; Rhodes, B; Smith, V; Thompson, R; Walters, K | 1 |
| Barzał, J; Gawroński, K; Młot, B; Oborska, S; Rzepecki, P; Szczylik, C; Waśko-Grabowska, A | 1 |
| Asaka, M; Imamura, M; Ito, S; Morita, A; Murata, N; Ogasawara, R; Sasaki, J; Senoo, N; Tanaka, J; Tsutsumi, Y | 1 |
| Buffet, M; Coman, T; Coppo, P; Garderet, L; Gorin, NC; Isnard, F; Malak, S; Ronchetti, AM | 1 |
| Badros, A; Barlogie, B; Morris, C; Tricot, G; Zangari, M | 1 |
| Baccarani, M; Benni, M; Cavo, M; Cellini, C; Fiacchini, M; Gozzetti, A; Ronconi, S; Tosi, P; Tura, S; Zamagni, E | 1 |
| Anaissie, E; Barlogie, B; Desikan, R; Fassas, AB; Spencer, T; Tricot, G; Zangari, M | 1 |
| Arcaini, L; Caberlon, S; Corso, A; Lazzarino, M; Lorenzi, A; Maiocchi, MA; Mangiacavalli, S; Morra, E; Pascutto, C; Rusconi, C; Troletti, D; Zappasodi, P | 1 |
| Briggs, A; Chow, HH; Dorr, RT; Kintzel, P; List, A; Meyers, R | 1 |
| Cogle, CR; Finiewicz, KJ; Khan, SA; Leather, HL; Moreb, JS; Reddy, VS; Wingard, JR | 1 |
| Barlogie, B; Eddleman, P; Fassas, A; Fink, L; Jacobson, J; Lee, CK; Talamo, G; Thertulien, R; Tricot, G; Van Rhee, F; Zangari, M | 1 |
| Mehta, J; Pichardo, D; Rosen, S; Singhal, S | 1 |
| Awedan, A; Blajer, B; Król, M; Rokicka, M; Torosian, T; Urbanowska, E; Wiktor-Jedrzejczak, W | 1 |
| Hussein, M | 1 |
| Balayre, S; Dighiero, P; Gicquel, JJ; Mercie, M | 1 |
| Amodeo, R; Anghel, G; De Rosa, L; Majolino, I; Pandolfi, A; Riccardi, M | 1 |
| Dalton, WS; Engel, R; Gump, JL; Hazlehurst, L; Sullivan, DM; Valkov, NI | 1 |
| Cottler-Fox, M; Fassas, A; Gojo, I; Guo, C; Heyman, M; Meisenberg, B; Rapoport, AP; Sarkodee-Adoo, C; Takebe, N; Tricot, G | 1 |
| Ardeshna, KM; Bhattacharya, S; D'Sa, S; Foulkes, B; Goldstone, AH; Ings, SJ; Kyriakou, C; Peggs, KS; Watts, MJ; Williams, CD; Yong, K | 1 |
| Delorme, S; Düber, C; Goldschmidt, H; Heiss, J; Hillengass, J; Kauczor, HU; Moehler, T; Neben, K; Nosas, S; Wasser, K | 1 |
| Koay, ES; Lau, LG; Liu, TC; Salto-Tellez, M; Tan, LK | 1 |
| Albiero, E; Castaman, G; Elice, F; Madeo, D; Novella, E; Roberti, S; Rodeghiero, F | 1 |
| Dans, K; Hamaguchi, H; Hiruma, K; Kojima, H; Mitani, K; Mori, S; Mukai, H; Nakamura, N; Nakamura, Y; Saito, K; Sakamaki, H; Tomiyama, J; Toyota, S | 1 |
| Alessandrino, EP; Banfi, L; Barbarano, L; Cairoli, R; Corso, A; De Paoli, A; Fava, S; Ferrari, D; Fiumanò, M; Frigerio, G; Isa, L; Klersy, C; Lazzarino, M; Luraschi, A; Mangiacavalli, S; Morra, E; Perego, D; Pinotti, G; Savarè, M; Ucci, G; Uziel, L; Vergani, C; Vismara, A; Zappasodi, P | 1 |
| Hussein, MA | 1 |
| Cahn, JY; Coutet, J; Deconinck, E; Limat, S; Voillat, L; Woronoff-Lemsi, MC | 1 |
| Anagnostopoulos, A; Anastasiou-Nana, MI; Dimopoulos, AM; Matsouka, C; Terrovitis, JV | 1 |
| Rao, PS | 1 |
| Alsina, M; Beaupre, DM; Buzzeo, R; Dalton, WS; Enkemann, S; Lichtenheld, MG; Nimmanapalli, R | 1 |
| Albarello, A; Ballerini, F; Balocco, M; Canepa, L; Canepa, P; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Varaldo, R | 1 |
| Glasmacher, A; von Lilienfeld-Toal, M | 1 |
| Astori, C; Bonfichi, M; Cafro, AM; Castagnola, C; Corso, A; Lazzarino, M; Mangiacavalli, S; Morra, E; Nosari, A; Pascutto, C; Rusconi, C; Troletti, D; Varettoni, M; Zappasodi, P | 1 |
| Cottler-Fox, M; Fassas, A; Fenton, R; French, T; Gojo, I; Guo, C; Heyman, M; Meisenberg, B; Murthy, A; Philips, GL; Rapoport, AP; Ruehle, K; Sarkodee-Adoo, C; Takebe, N; Tan, M; Tricot, G | 1 |
| Assouline, S; Carriere, P; Laneuville, P; Shustik, C; Sylvestre, MP | 1 |
| Kunihiko, M; Mariko, Y; Shinichiro, O; Yasuo, I; Yusuke, T; Yutaka, H | 1 |
| Beguin, Y; Fillet, G; Frère, P; Ngirabacu, MC; Vanstraelen, G; Willems, E | 1 |
| Bohlius, J; Engert, A; Hülsewede, H; Kober, T | 1 |
| Bang, SM; Kim, DH; Kim, H; Kim, K; Kim, S; Lee, JH; Lee, JJ; Sohn, HJ; Sohn, SK; Suh, C | 1 |
| Arpaci, F; Ataergin, S; Cetin, T; Gunhan, O; Kaya, A; Kaya, T | 1 |
| Blechschmidt, M; Bornhäuser, M; Ehninger, G; Hänel, M; Hölig, K; Kroschinsky, F; Oelschlaegel, U; Ordemann, R; Platzbecker, U; Poppe-Thiede, K; Schaich, M | 1 |
| Avalos, B; Benson, DM; Blum, W; Copelan, E; Elder, PJ; Farag, SS; Lin, TS; Penza, S | 1 |
| Amitani, Y; Hashimoto, C; Hyo, R; Kobayashi, S; Maruta, A; Motomura, S; Sakai, R; Tamura, T; Tanaka, M | 1 |
| Florschütz, A; Kachel, R; Knolle, J; Schelle, M; Schreiber, C; Schreiber, J | 1 |
| Akpek, G; Badros, A; Fenton, R; Goloubeva, O; Harris, C; Meisenberg, B; Rapoport, AP; Ruehle, K; Westphal, S | 1 |
| Delgado-Lamas, JL; García-Ruiz-Esparza, MA; Gómez-Almaguer, D; Gómez-Rangel, D; Gutiérrez-Aguirre, CH; Morales-Toquero, A; Padilla-González, Y; Ruiz-Argüelles, GJ; Ruiz-Delgado, GJ; Vela-Ojeda, J | 1 |
| Alsayed, Y; Anaissie, E; Barlogie, B; Bolejack, V; Crowley, J; Epstein, J; Hollmig, K; Mohiuddin, A; Pineda-Roman, M; Shaughnessy, JD; Tricot, G; van Rhee, F; Woods, G; Zangari, M | 1 |
| Andreesen, R; Blank, C; Hart, C; Hennemann, B; Krause, SW | 1 |
| Aoyama, T; Hagiwara, S; Imataki, O; Inoue, N; Kataoka, T; Katsumata, M; Katsuta, T; Kawakami, K; Mochizuki, T; Motokawa, S; Tamai, Y; Yoshida, T | 1 |
| Biriukova, LS; Chavynchak, RB; Rekhtina, IG; Ryzhko, VV | 1 |
| Aoyama, T; Imataki, O; Kawakami, K; Tamai, Y | 1 |
| Astori, C; Bonfichi, M; Ciapanna, D; Corso, A; Lazzarino, M; Mangiacavalli, S; Morra, E; Nosari, AM; Varettoni, M; Zappasodi, P | 1 |
| Bacon, P; Blijlevens, N; D'Addio, A; Einsele, H; Maertens, J; McCann, S; Niederwieser, D; Quinn, B; Rabitsch, W; Roosaar, A; Ruutu, T; Schouten, H; Schwenkglenks, M; Stone, R; Vokurka, S | 1 |
| Anaissie, EJ; Barlogie, B; Coleman, EA; Coon, SK; Kennedy, RL; Lockhart, KD; Stewart, CB | 1 |
| Barlogie, B; Cabanillas, F; Freireich, EJ; Keating, M | 1 |
| Chapman, CS; Ghosh, K; Murphy, P; Sivakumaran, M; Wood, JK | 1 |
| Grau, E; Real, E; Torrecillas, MT | 1 |
| Kaya, H; Kumabashiri, I; Matsuda, T; Nakamura, S; Ohtake, S; Yamazaki, H | 1 |
| Adel, AL; Dorr, RT; Liddil, JD | 1 |
| Fujii, H; Kuzuyama, Y; Maekawa, T; Nakagawa, H; Sonoda, Y | 1 |
| Boccadoro, M; Bondesan, P; Bregni, M; Caracciolo, D; Frieri, R; Gianni, AM; Omedé, P; Pileri, A; Siena, S; Tarella, C | 1 |
| Berenson, J; Fady, C; Lichtenstein, A; Tu, Y; Vescio, R | 1 |
| Ganjoo, RK; Malpas, JS; Williams, A | 1 |
| Alexanian, R; Champlin, R; Delasalle, K; Dimopoulos, MA; Hester, J; Weber, DM | 1 |
| Adkins, DR; Boldt, D; Freytes, CO; Irvin, R; Kuhn, J; LeMaistre, CF; Lyons, R; Roodman, GD; Salzman, D; Smith, L | 1 |
| Barbot, C; Jazwiec, B; Mahon, FX; Reiffers, J; Rice, A; Vanès, I | 1 |
| Alexanian, R; Champlin, R; Delasalle, K; Dimopoulos, MA; Hester, J | 1 |
| Cottler-Fox, M; Cowan, K; Dunbar, CE; Goodman, S; Leitman, S; Nienhuis, AW; O'Shaughnessy, J; Quesenberry, P; Sorrentino, BP; Stewart, FM | 1 |
| Akkoc, N; Altungoz, O; Cehreli, C; Onvural, B; Undar, B | 1 |
| Björeman, M; Björkholm, M; Brenning, G; Carlson, K; Celsing, F; Gahrton, G; Grimfors, G; Juliusson, G; Ohrling, M; Osterborg, A | 1 |
| Arima, T; Hanada, S; Makino, T; Nakahara, K; Shimotakahara, S; Takeshita, T; Tokiwa, F; Utsunomiya, A | 1 |
| Alexanian, R; Champlin, R; Delasalle, KB; Dimopoulos, MA | 1 |
| Ganjoo, RK; Malpas, JS; Plowman, PN | 1 |
| Benedetti, G; Bondesan, P; Caracciolo, D; Castellino, C; Cherasco, C; Gianni, AM; Omedé, P; Pileri, A; Ruggieri, D; Tarella, C | 1 |
| Kamijima, S; Kato, Y; Kobayashi, H; Kuwahara, M; Mihara, H; Nagasaka, T; Oguri, T; Takeda, H | 1 |
| Ager, S; Baglin, TP; Bass, G; Mahendra, P; Marcus, RE; Richards, EM | 1 |
| Garćia, J; Grañena, A; Palou, J; Sarrá, J; Valls, A; Vivancos, P | 1 |
| Berenson, J; Fady, C; Lichtenstein, A; Liu, J; Tu, Y; Vescio, R; Xu, FH | 1 |
| Cattan, AR; Maung, ZT | 1 |
| Björkholm, M; Gruber, A; Liliemark, E; Liliemark, J; Osby, E; Peterson, C; Sirzea, F; Söderhäll, S; Zhou, R | 1 |
| Blume, KG; Chao, NJ; Hu, WW; Long, GD; Negrin, RS; Wong, RM | 1 |
| Ballester, OF; Elfenbein, GJ; Fields, KK; Goldstein, SC; Hiemenz, JW; Kronish, L; Moscinski, LC; Saba, HI; Spiers, AS; Sullivan, P; Zorsky, PE | 1 |
| Fleming, DR; Mangino, PB | 1 |
| Cianfriglia, M; Frey, BM; Gieseler, F; Lehnert, M; Scheper, RJ; Schmid, L; Schneider, E; Shao, Y; Twentyman, PR; Wyler, B | 1 |
| Engelhardt, M; Henschler, R; Lange, W; Mertelsmann, R; Waller, C; Winkler, J | 1 |
| Mizoguchi, H; Wada, M | 1 |
| Barlogie, B; Bracy, D; Desikan, KR; Jagannath, S; Mattox, S; Mehta, J; Munshi, N; Siegel, D; Singhal, S; Tricot, G; Vesole, D | 1 |
| Abella, E; Adams, PT; al-Katib, A; Dragovic, J; Du, W; Janakiraman, N; Karanes, C; Raman, SB; Ratanatharathorn, V; Sensenbrenner, L; Silver, SM; Uberti, J; Varterasian, M | 1 |
| Alcorn, MJ; Cook, G; Farrell, E; Franklin, IM; Marinaki, P; Pearson, C; Sharp, RA; Tansey, PJ | 1 |
| Barlogie, B; Bracy, D; Desikan, KR; Fassas, A; Jagannath, S; Mattox, S; Mehta, J; Munshi, N; Nelson, J; Siegel, D; Singhal, S; Tindle, S; Tricot, G; Vesole, DH | 1 |
| Abboudi, Z; Abrahamson, G; Apperley, JF; Chilcott, S; Craddock, C; Davis, J; Kanfer, EJ; MacDonald, C; Macdonald, D; McGuigan, D; Newlands, ES; Olavarria, E; Philpott, N; Rustin, GJ; Samson, D; Seckl, MJ; Sekhar, M; Stern, S | 1 |
| Anaissie, E; Ayers, D; Barlogie, B; Cheson, B; Cromer, J; Crowley, J; Desikan, KR; Dhodapkar, D; Epstein, J; Fassas, A; Jagannath, S; Mattox, S; Mehta, J; Munshi, N; Naucke, S; Sawyer, J; Siegel, D; Singhal, S; Spoon, D; Tricot, G; Vesole, D | 1 |
| Kiss, I; Tomasek, J | 1 |
| Belt, R; Coon, J; Cord, M; Dix, S; Geller, R; Howard, S | 1 |
| Giles, FJ; Lim, SW; Lynott, AM; Rapoport, BL; Shan, J; Somlo, G; Wickham, NR | 1 |
| Engel, R; Gump, JL; Sullivan, DM; Valkov, NI | 1 |
| Bos, NA; de Wolf, JT; Guikema, JE; Hovenga, S; Klip, H; Smit Sibinga, CT; Smit, JW; Vellenga, E | 1 |
| Buyuksal, I; Cantor, AB; Dalton, WS; Landowski, TH; Shain, KH | 1 |
| Ayala-Sánchez, M; Esparza, MA; García-León, LD; González-Llaven, J; Guevara-Moreno, ME; Montiel-Cervantes, L; Rosas-Cabral, A; Sánchez-Cortés, E; Tripp-Villanueva, F; Vela-Ojeda, J | 1 |
| Fukuno, K; Moriwaki, H; Oyama, M; Tsurumi, H; Yamada, T | 1 |
| Butch, AW; Flick, JT; Pappas, AA; Yeh, YA | 1 |
| Giebel, S; Hołowiecki, J; Kachel, L; Kata, D; Krawczyk-Kuliś, M; Markiewicz, M; Wojciechowska, M; Wojnar, J | 1 |
| Benner, A; Egerer, G; Goldschmidt, H; Hawighorst, H; Hillengass, J; Ho, AD; Max, R; Moehler, TM; Neben, K; van Kaick, G | 1 |
| Harada, N; Hata, H; Matsuzaki, H; Otsuki, T; Ueki, A; Wada, H; Yamada, O; Yata, K; Yawata, Y | 1 |
| Benboubker, L; Colombat, P; Dugay, J; Gauvain, JB; Goupille, P; Linassier, C; Lucas, V; Luthier, F; Maigre, M; Rodon, P | 1 |
| Buxhofer, V; Hinterberger, W; Hübl, G; Kier, P; Kittl, E; Ruckser, R; Tatzreiter, G; Vedovelli, H; Zelenka, P | 1 |
| Abraham, R; Chen, CI; Crump, M; Keating, A; Stewart, AK; Tsang, R | 1 |
| Chen, F; Kadowaki, S; Kageyama, SI; Katayama, N; Kita, K; Masuya, M; Mitani, H; Nishii, K; Shiku, H; Usui, E | 1 |
| Bilgrami, S; Bona, RD; Clive, J; Edwards, RL; Fox, J; Furlong, F; Li, Z; Naqvi, B; Shaikh, A; Tutschka, PJ | 1 |
| Anaissie, E; Badros, A; Barlogie, B; Desikan, R; Fink, L; Gopal, AV; Morris, C; Siegel, E; Toor, A; Tricot, G; Zangari, M | 1 |
| Cottler-Fox, M; Fassas, A; Gojo, I; Meisenberg, B; Papadimitriou, JC; Rapoport, A; Tricot, G | 1 |
| Bensinger, WI; Gooley, T; Heimfeld, S; Holmberg, L; Maloney, D; Rowley, SD; Yu, J | 1 |
| D'Orazio, AI | 1 |
| Benner, A; Egerer, G; Goldschmidt, H; Ho, AD; Krasniqi, F; Moehler, TM; Neben, K | 1 |
| Bonavida, B; Gan, XH; Jazirehi, AR; Ng, CP; Schiller, G | 1 |
| Alessandrino, EP; Barbarano, L; Cairoli, R; Corso, A; Fava, S; Ferrari, D; Fiumanò, M; Frigerio, G; Isa, L; Lazzarino, M; Luraschi, A; Montanara, S; Morandi, S; Morra, E; Perego, D; Pinotti, G; Rodeghiero, F; Santagostino, A; Savarè, M; Ucci, G; Uziel, L; Vismara, A | 1 |
| Anaissie, E; Badros, A; Barlogie, B; Desikan, R; Fassas, A; Fink, L; Mehta, P; Morris, C; Saghafifar, F; Siegel, E; Toor, A; Tricot, G; Whitfield, D; Zangari, M | 1 |
| Balleari, E; Ballestrero, A; Clavio, M; Ferrando, F; Garuti, A; Ghio, R; Gobbi, M; Gonella, R; Grasso, R; Miglino, M; Patrone, F | 1 |
| Drach, J; Kaufmann, H; Nösslinger, T; Raderer, M; Urbauer, E | 1 |
| Bonadonna, G; Bregni, M; Di Nicola, M; Gianni, AM; Lombardi, F; Magni, M; Pileri, A; Siena, S; Tarella, C | 1 |
| Blume, KG; Forman, SJ | 1 |
| Dalton, WS; Grogan, TM; Lehnert, M; Miller, TP; Plezia, P; Roe, DJ; Salmon, SE | 1 |
| Barlogie, B; Beckord, J; Crowley, J; Pugh, RP; Salmon, SE | 1 |
| Alexanian, R; Barlogie, B; Dicke, KA; Hester, JP; Horwitz, LH; LeMaistre, CF; Spinolo, JA; Ventura, GJ; Wallerstein, RO; Yau, JC | 1 |
| Clarkson, BD; Fried, J; Fujita, N; Gulati, SC; Inaba, T; Murakami, S; Nakagawa, M; Shimazaki, C; Wang, CY; Wisniewolski, R | 1 |
| Barlogie, B | 1 |
| Benbunan, M; Brouet, JC; Castaigne, S; Cosset, JM; Fermand, JP; Gerota, J; Lévy, Y; Seligmann, M | 1 |
| Atzpodien, J; Clarkson, BD; Gulati, SC; Lemoli, RM; Shimazaki, C | 1 |
| Alexanian, R; Barlogie, B; Cabanillas, F; Velasquez, WS | 1 |
| Phillips, JK | 1 |
| Dorr, RT; Gerner, EW; Liddil, JD | 1 |
| Bartolucci, AA; Gockerman, JP; Nelson, MO; Silberman, H; Stein, R; Velez-Garcia, E | 1 |
| Boll, J; Deicher, H; Essers, U; Gamm, H; Glück, S; Görg, K; Gramatzki, M; Peest, D; Schedel, I; Schmoll, HJ | 1 |
12 review(s) available for etoposide and Multiple Myeloma
| Article | Year |
|---|---|
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cisplatin; Cyclophosphamide; Dexamethasone; Disease Management; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Plasmacytoma; Prognosis; Transplantation, Autologous | 2021 |
How to treat a newly diagnosed young patient with multiple myeloma.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Disease Management; Doxorubicin; Endpoint Determination; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Middle Aged; Molecular Diagnostic Techniques; Multicenter Studies as Topic; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide; Transplantation Conditioning | 2009 |
Recent developments and future directions in the treatment of multiple myeloma.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Clinical Trials as Topic; Cysteine Endopeptidases; Diphosphonates; Doxorubicin; Erythropoietin; Etoposide; Forecasting; Humans; Interferons; Multienzyme Complexes; Multiple Myeloma; Organometallic Compounds; Organophosphorus Compounds; Oxides; Peripheral Blood Stem Cell Transplantation; Proteasome Endopeptidase Complex; Thalidomide; Tissue Extracts | 2003 |
Pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone as first-line therapy for multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Humans; Liposomes; Microcirculation; Middle Aged; Multiple Myeloma; Time Factors; Treatment Outcome | 2003 |
T-cell post-transplant lymphoproliferative disorder after hematopoietic stem cell transplantation: another case and a review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Humans; Lymphoproliferative Disorders; Male; Multiple Myeloma; Stem Cell Transplantation; T-Lymphocytes | 2004 |
The current status of thalidomide in the management of multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Tumor Necrosis Factor-alpha | 2005 |
Fourth biannual report of the Cochrane Haematological Malignancies Group.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Europe; Hematologic Neoplasms; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Meta-Analysis as Topic; Multicenter Studies as Topic; Multiple Myeloma; National Institutes of Health (U.S.); Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Procarbazine; Pyrazines; Randomized Controlled Trials as Topic; Rituximab; Stem Cell Transplantation; Transplantation, Autologous; United States; Vinblastine; Vincristine | 2006 |
The hematologic malignancies. Leukemia, lymphoma, and myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Interferons; Leukemia; Lymphoma; Mechlorethamine; Multiple Myeloma; Prednisone; Procarbazine; Prognosis; Translocation, Genetic; Vincristine | 1984 |
Coexistence of chronic neutrophilic leukemia with light chain myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Doxorubicin; Etoposide; Female; Humans; Hydroxyurea; Immunoglobulin kappa-Chains; Leukemia, Neutrophilic, Chronic; Middle Aged; Multiple Myeloma; Neoplasms, Multiple Primary | 1994 |
[Progress in the treatment of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cisplatin; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Humans; Interferon-alpha; Melphalan; Multiple Myeloma; Prednisone; Remission Induction; Vincristine | 1997 |
Multiple myeloma in elderly patients: presenting features and outcome.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Comorbidity; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; France; Humans; Interferon-alpha; Life Tables; Lomustine; Male; Melphalan; Multiple Myeloma; Myeloma Proteins; Neoplasm Staging; Paraneoplastic Syndromes; Prednimustine; Prednisone; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Treatment Outcome; Vincristine | 2001 |
High-dose etoposide (VP-16)-containing preparatory regimens in allogeneic and autologous bone marrow transplantation for hematologic malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chemotherapy, Adjuvant; Etoposide; Humans; Leukemia; Lymphoma; Multiple Myeloma; Whole-Body Irradiation | 1992 |
49 trial(s) available for etoposide and Multiple Myeloma
| Article | Year |
|---|---|
High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) Conditioning Before Autologous Transplantation for Patients With Multiple Myeloma.
Topics: Bendamustine Hydrochloride; Cytarabine; Drug Therapy, Combination; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Transplantation, Autologous | 2022 |
Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; Etoposide; Humans; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies | 2022 |
[Bortezomib-based combination therapy for relapsed or refractory multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Constipation; Cyclophosphamide; Dexamethasone; Dizziness; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fatigue; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide; Treatment Outcome | 2008 |
EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells.
Topics: Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Epirubicin; Erythropoietin; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Leukapheresis; Leukocyte Count; Leukocytes; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prospective Studies; Recombinant Proteins | 2009 |
Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Combined Modality Therapy; Constipation; Cyclophosphamide; Dexamethasone; Diarrhea; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Infections; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Transplantation, Autologous; Treatment Outcome | 2010 |
Efficiency of supersaturated calcium phosphate mouth rinse treatment in patients receiving high-dose melphalan or BEAM prior to autologous blood stem cell transplantation: a single-center experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Calcium Phosphates; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mouthwashes; Multiple Myeloma; Stomatitis; Transplantation Conditioning; Treatment Outcome; Young Adult | 2011 |
Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Female; Humans; Male; Melphalan; Middle Aged; Mitoxantrone; Multiple Myeloma; Prednisone; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Rate; Time Factors; Treatment Outcome | 2002 |
Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Etoposide; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2002 |
Comparative pharmacokinetic study of high-dose etoposide and etoposide phosphate in patients with lymphoid malignancy receiving autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chromatography, High Pressure Liquid; Etoposide; Hodgkin Disease; Humans; Life Expectancy; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Multiple Myeloma; Organophosphorus Compounds; Stem Cell Transplantation; Time Factors; Transplantation, Autologous | 2003 |
Evaluation of relative anti-myeloma activity of high-dose melphalan followed by the first peripheral blood stem cell transplantation, as compared with the second transplantation, and to VAD chemotherapy.
Topics: ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Adult; Aged; Antibodies, Monoclonal; Antigens, CD; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bone Marrow Cells; Combined Modality Therapy; Doxorubicin; Etoposide; Female; Flow Cytometry; Humans; Immunoglobulin G; Male; Melphalan; Membrane Glycoproteins; Middle Aged; Multiple Myeloma; Stem Cell Transplantation | 2003 |
High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Treatment Outcome | 2004 |
[Dynamic MRI of the bone marrow for monitoring multiple myeloma during treatment with thalidomide as monotherapy or in combination with CED chemotherapy].
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Bone Marrow; Cyclophosphamide; Data Interpretation, Statistical; Dexamethasone; Drug Therapy, Combination; Etoposide; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Magnetic Resonance Imaging; Male; Microcirculation; Middle Aged; Multiple Myeloma; Prospective Studies; Remission Induction; Thalidomide; Time Factors; Treatment Outcome | 2004 |
Effect of DCEP mobilizing regimen in in vivo purging of PBSC harvests in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome; Vincristine | 2004 |
[Autologous peripheral blood stem cell transplantation for Japanese multiple myeloma patients: results of a feasibility study].
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Feasibility Studies; Granulocyte Colony-Stimulating Factor; Humans; Japan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Vincristine | 2004 |
The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Neutropenia; Thrombocytopenia; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2004 |
Efficacy, toxicity and feasibility of a shorter schedule of DCEP regimen for stem cell mobilization in multiple myeloma.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; Drug Administration Schedule; Etoposide; Feasibility Studies; Hematopoietic Stem Cell Mobilization; Humans; Infections; Multiple Myeloma; Neutropenia; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Thrombocytopenia | 2005 |
Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation.
Topics: Antineoplastic Agents; Cyclophosphamide; Etoposide; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Multiple Myeloma; Polyethylene Glycols; Recombinant Proteins; Transplantation, Autologous | 2006 |
Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Transplantation, Autologous; Treatment Outcome | 2006 |
Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Male; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2006 |
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Proteins; Bone Marrow; Boronic Acids; Bortezomib; Cisplatin; Creatinine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous | 2007 |
DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Injections, Subcutaneous; Leukapheresis; Male; Middle Aged; Multiple Myeloma; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome | 2008 |
Effects of exercise in combination with epoetin alfa during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for multiple myeloma.
Topics: Adult; Aged; Analysis of Variance; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Epoetin Alfa; Erythropoietin; Etoposide; Exercise Test; Exercise Therapy; Fatigue; Female; Hematinics; Humans; Male; Middle Aged; Multiple Myeloma; Nurse's Role; Nursing Evaluation Research; Oncology Nursing; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Treatment Outcome; Vincristine | 2008 |
Vincristine and oral etoposide in refractory multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance; Etoposide; Female; Humans; Male; Middle Aged; Multiple Myeloma; Vincristine | 1995 |
Intensive sequential therapy for VAD-resistant multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Drug Resistance; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Prognosis; Vincristine | 1994 |
Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Hypocalcemia; Hypotension; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Remission Induction; Transplantation, Autologous | 1994 |
Etoposide, doxorubicin, cyclophosphamide and high-dose betamethasone (EACB) as outpatient salvage therapy for refractory multiple myeloma.
Topics: Actuarial Analysis; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Betamethasone; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Resistance; Etoposide; Follow-Up Studies; Humans; Middle Aged; Multiple Myeloma; Neoplasm Staging; Recurrence; Salvage Therapy; Survival Analysis; Time Factors | 1993 |
Cyclophosphamide and etoposide therapy with GM-CSF for VAD-resistant multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Resistance; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Middle Aged; Multiple Myeloma; Salvage Therapy; Time Factors; Vincristine | 1993 |
Dexamethasone, cyclophosphamide, idarubicin and etoposide (DC-IE): a novel, intensive induction chemotherapy regimen for patients with high-risk multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Etoposide; Female; Humans; Idarubicin; Male; Middle Aged; Multiple Myeloma; Neutropenia; Survival Rate; Treatment Outcome | 1997 |
Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cell Separation; Combined Modality Therapy; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Transplantation, Autologous | 1997 |
High-dose chemotherapy with carboplatin, cyclophosphamide and etoposide and autologous transplantation for multiple myeloma relapsing after a previous transplant.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Prognosis; Recurrence | 1997 |
Transplantation in patients with multiple myeloma: a multicenter comparative analysis of peripheral blood stem cell and allogeneic transplant.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Carmustine; Cause of Death; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Whole-Body Irradiation | 1997 |
Peripheral blood progenitor cell mobilisation in patients with multiple myeloma following oral idarubicin and dexamethasone (Z-Dex) induction therapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colony-Forming Units Assay; Cyclophosphamide; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Etoposide; Female; Flow Cytometry; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Male; Mesna; Middle Aged; Multiple Myeloma; Remission Induction | 1997 |
Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Kinetics; Leukocyte Count; Melphalan; Middle Aged; Multiple Myeloma; Prospective Studies | 1998 |
High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: efficacy and toxicity at three dose levels.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Etoposide; Female; Germinoma; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hodgkin Disease; Humans; Leukemia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Neoplasms | 1998 |
Total therapy with tandem transplants for newly diagnosed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prognosis; Remission Induction; Treatment Outcome; Vincristine | 1999 |
Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Survival Analysis; Treatment Outcome; Vincristine | 2000 |
Prospective randomized clinical trial comparing high-dose ifosfamide + GM-CSF vs high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cryopreservation; Cyclophosphamide; Cytarabine; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Recombinant Proteins; Regression Analysis; Survival Rate; Transplantation, Autologous | 2000 |
Ifosfamide, etoposide, epirubicine, and G-CSF: an effective mobilization regimen for PBSCT in heavily pretreated patients.
Topics: Adult; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma | 2000 |
[Functional magnetic resonance tomography in the diagnosis and therapy monitoring in multiple myeloma].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Dexamethasone; Drug Monitoring; Etoposide; Humans; Ilium; Immunohistochemistry; Lumbar Vertebrae; Magnetic Resonance Imaging; Microcirculation; Multiple Myeloma; Thalidomide | 2000 |
[High dosage chemotherapy with autologous stem cell transplantation in multiple myeloma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Survival Rate; Treatment Outcome | 2000 |
Dexamethasone, paclitaxel, etoposide, cyclophosphamide (d-TEC) and G-CSF for stem cell mobilisation in multiple myeloma.
Topics: Adult; Aged; Antiemetics; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Lorazepam; Male; Middle Aged; Multiple Myeloma; Ondansetron; Paclitaxel; Taxoids; Transplantation, Autologous | 2001 |
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.
Topics: Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation Factors; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Male; Middle Aged; Multiple Myeloma; Risk; Risk Factors; Thalidomide; Venous Thrombosis; Vincristine | 2001 |
Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.
Topics: Activated Protein C Resistance; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation Tests; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Factor V; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Life Tables; Male; Middle Aged; Multiple Myeloma; Risk; Thalidomide; Thrombophilia; Venous Thrombosis; Vincristine | 2002 |
Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clone Cells; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; DNA, Neoplasm; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Mitoxantrone; Multiple Myeloma; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2002 |
Thromboembolic events during treatment with thalidomide.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Humans; Lymphoma, Mantle-Cell; Multiple Myeloma; Prednisone; Rituximab; Thalidomide; Thromboembolism; Vincristine | 2002 |
Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Etoposide; Humans; Immunohistochemistry; Membrane Glycoproteins; Multiple Myeloma; Verapamil | 1991 |
alpha-Interferon for remission maintenance: preliminary report on the Southwest Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Humans; Interferon-alpha; Melphalan; Multiple Myeloma; Prednisone; Remission Induction; Vincristine | 1991 |
Phase II evaluation of etoposide in refractory multiple myeloma: a Southeastern Cancer Study Group Trial.
Topics: Clinical Trials as Topic; Drug Evaluation; Etoposide; Female; Hematologic Diseases; Humans; Male; Middle Aged; Multiple Myeloma; Podophyllotoxin | 1986 |
Current results of a multicenter trial in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Random Allocation; Vincristine | 1986 |
125 other study(ies) available for etoposide and Multiple Myeloma
| Article | Year |
|---|---|
The Safety and Efficacy of Radiation Therapy with Concurrent Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin-Based Systemic Therapy for Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Etoposide; Humans; Multiple Myeloma; Treatment Outcome | 2022 |
Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide as a Salvage and Bridging Regimen before Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Retrospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2022 |
Bridging advanced myeloma patients to subsequent treatments and clinical trials with classical chemotherapy and stem cell support.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Myeloma; Transplantation, Autologous | 2023 |
[Analysis of Related Factors of Autologous Peripheral Hematopoietic Stem Cell Mobilization in Patients with Lymphoma and Myeloma].
Topics: Etoposide; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma; Male; Multiple Myeloma; Retrospective Studies | 2022 |
Cyclophosphamide etoposide dexamethasone as salvage and bridging therapy in relapsed refractory and extramedullary multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Salvage Therapy; Transplantation, Autologous | 2023 |
[Comparison of etoposide combined with G-CSF and cyclophosphamide combined with G-CSF in mobilization of autologous peripheral hematopoietic stem cells in patients with newly diagnosed multiple myeloma].
Topics: Antigens, CD34; Cyclophosphamide; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Multiple Myeloma; Transplantation, Autologous | 2022 |
Acquired haemophagocytic lymphohistiocytosis secondary to multiple myeloma.
Topics: Antineoplastic Agents, Phytogenic; Dexamethasone; Drug Therapy, Combination; Etoposide; Fatal Outcome; Glucocorticoids; Humans; Lymphohistiocytosis, Hemophagocytic; Male; Middle Aged; Multiple Myeloma | 2019 |
The VR-DCEP regimen rescues mobilization failures and controls refractory disease in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Multiple Myeloma; Virtual Reality | 2020 |
DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cisplatin; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Etoposide; Female; Humans; Male; Middle Aged; Multiple Myeloma; Prednisolone; Retrospective Studies; Salvage Therapy; Survival Rate | 2020 |
DPACE-based chemotherapy in the era of myeloma novel agents: A UK multicentre study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Multicenter Studies as Topic; Multiple Myeloma; Prognosis; Treatment Outcome; United Kingdom | 2020 |
Effective mobilization with etoposide and cyclophosphamide for collection of peripheral blood stem cell in patients with multiple myeloma.
Topics: Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Mobilization; Humans; Multiple Myeloma; Peripheral Blood Stem Cells; Retrospective Studies | 2020 |
Synchronous diagnosis of anaplastic large cell lymphoma and multiple myeloma in a patient: A case report.
Topics: Abdominal Wall; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Examination; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunohistochemistry; Lenalidomide; Lymphoma, Large-Cell, Anaplastic; Maintenance Chemotherapy; Middle Aged; Multiple Myeloma; Neoplasms, Multiple Primary; Positron Emission Tomography Computed Tomography; Prednisone; Remission Induction; Skin Neoplasms; Transplantation, Autologous; Vincristine | 2020 |
DT-PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Male; Methylprednisolone; Middle Aged; Multiple Myeloma; Progression-Free Survival; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Young Adult | 2021 |
Reduced-intensity conditioning allogeneic transplantation after salvage treatment with DT-PACE in myeloma patients relapsing early after autologous transplant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Recurrence; Retreatment; Survival Analysis; Thalidomide; Transplantation Chimera; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2017 |
New Painful Nodules in a Patient With Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cancer Pain; Cisplatin; Cyclophosphamide; Dexamethasone; Diagnosis, Differential; Etoposide; Female; Humans; Middle Aged; Multiple Myeloma; Neoplasm Staging; Plasmacytoma; Positron Emission Tomography Computed Tomography; Treatment Outcome; Ultrasonography, Interventional | 2017 |
Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Middle Aged; Multiple Myeloma; Salvage Therapy; Stem Cell Transplantation; Survival Analysis; Thalidomide; Treatment Outcome; Vincristine | 2018 |
Treatment of relapsed multiple myeloma complicated by cardiac extramedullary plasmacytoma with D-PACE chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Heart Neoplasms; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Plasmacytoma; Positron-Emission Tomography | 2018 |
Anaplastic multiple myeloma: possible limitations of conventional chemotherapy for long-term remission.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Middle Aged; Multiple Myeloma; Prednisone; Remission Induction; Vincristine | 2018 |
DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival | 2018 |
D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Salvage Therapy; Thalidomide; Treatment Outcome | 2013 |
[Busulfan, cyclophosphamide and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma].
Topics: Adult; Busulfan; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2013 |
Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Central Nervous System; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Injections, Spinal; Kaplan-Meier Estimate; Lenalidomide; Male; Meninges; Middle Aged; Multiple Myeloma; Orbit; Proportional Hazards Models; Pyrazines; Radiotherapy, Adjuvant; Retrospective Studies; Salvage Therapy; Spine; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine | 2013 |
Fifteenth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Cyclophosphamide; Dasatinib; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Non-Hodgkin; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Staging; Piperazines; Platelet Transfusion; Prednisone; Primary Prevention; Procarbazine; Pyrimidines; Randomized Controlled Trials as Topic; Rituximab; Stem Cell Transplantation; Survival Analysis; Thiazoles; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome; Vincristine; Vindesine | 2013 |
Myeloma presenting during pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cesarean Section; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Contraindications; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Humans; Hypercalcemia; Idarubicin; Infant, Newborn; Lenalidomide; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Myeloma Proteins; Osteolysis; Plasmacytoma; Postpartum Period; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrazines; Remission Induction; Spinal Cord Compression; Thalidomide; Thoracic Vertebrae; Transplantation, Autologous | 2014 |
DCEP for relapsed or refractory multiple myeloma after therapy with novel agents.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Evaluation; Drug Resistance, Neoplasm; Etoposide; Fatigue; Female; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Mucositis; Multiple Myeloma; Peripheral Nervous System Diseases; Recurrence; Retrospective Studies; Transplantation, Autologous; Treatment Outcome | 2014 |
The lymphoma-like polychemotherapy regimen "Dexa-BEAM" in advanced and extramedullary multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Disease-Free Survival; Drug Therapy, Combination; Etoposide; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Registries; Retrospective Studies | 2014 |
Visual problem and low back pain as initial manifestation of multiple myeloma complicating pre-existing systemic sclerosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Diplopia; Doxorubicin; Etoposide; Fatal Outcome; Humans; Low Back Pain; Magnetic Resonance Imaging; Male; Multiple Myeloma; Scleroderma, Systemic | 2014 |
First line and salvage therapy with total therapy 3-based treatment for multiple myeloma- an extended single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Salvage Therapy; Survival Rate; Thalidomide | 2014 |
Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses.
Topics: Adult; Aged; Aminocaproic Acid; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Carmustine; Combined Modality Therapy; Cyclophosphamide; Erythropoietin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hemoglobins; Humans; Iron; Jehovah's Witnesses; Lymphoma; Male; Melphalan; Middle Aged; Multiple Myeloma; Recurrence; Stem Cell Transplantation; Transplantation, Autologous; Vitamin K 1; Young Adult | 2015 |
A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Salvage Therapy; Survival Analysis; Thalidomide; Treatment Outcome; Vincristine | 2015 |
BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous | 2015 |
Efficacy and safety of stem cell mobilization with cyclophosphamide plus etoposide versus cyclophosphamide alone.
Topics: Adult; Aged; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Male; Middle Aged; Multiple Myeloma; Retrospective Studies | 2015 |
Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Male; Middle Aged; Multiple Myeloma; Recurrence; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous | 2008 |
Hepatic veno-occlusive disease after tandem autologous stem cell transplantation conditioned by melphalan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Etoposide; Hepatic Veno-Occlusive Disease; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous | 2008 |
The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT.
Topics: Adult; Aged; Analgesics, Opioid; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Humans; Length of Stay; Lymphoma, Non-Hodgkin; Male; Medical Audit; Melphalan; Middle Aged; Multiple Myeloma; Prospective Studies; Risk Factors; Stem Cell Transplantation; Stomatitis; Transplantation Conditioning | 2009 |
Contamination of autologous peripheral blood progenitor cell grafts predicts overall survival after high-dose chemotherapy in multiple myeloma.
Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Ifosfamide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Survival Analysis; Syndecan-1; Transplantation, Autologous; Young Adult | 2009 |
Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mucositis; Multiple Myeloma; Neoplasms; Severity of Illness Index; Whole-Body Irradiation; Young Adult | 2009 |
Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
Topics: Activated Protein C Resistance; Angiogenesis Inhibitors; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Doxorubicin; Etoposide; Factor V; Follow-Up Studies; Humans; Hyperhomocysteinemia; Multiple Myeloma; Prednisone; Pulmonary Embolism; Retrospective Studies; Thalidomide; Thrombophilia; Venous Thrombosis | 2009 |
Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Topoisomerases, Type II; Drug Synergism; Etoposide; Humans; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Topoisomerase II Inhibitors | 2009 |
Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Bone Marrow; Combined Modality Therapy; Cyclams; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Ifosfamide; Lenalidomide; Leukapheresis; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Retrospective Studies; Risk Factors; Thalidomide; Transplantation, Autologous; Treatment Failure; Vincristine | 2009 |
Total therapy-based treatment for multiple myeloma--a single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2010 |
[One hundred fifty autologous peripheral haemopoietic stem cell transplantations and their lessons].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Hungary; International Cooperation; Kaplan-Meier Estimate; Leiomyosarcoma; Lymphoma, Non-Hodgkin; Melphalan; Multiple Myeloma; Nitrosourea Compounds; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2009 |
Acute myeloid leukemia complicating multiple myeloma: a case successfully treated with etoposide, thioguanine, and cytarabine.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Multiple Myeloma; Remission Induction; Thioguanine | 2009 |
Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Combined Modality Therapy; Creatinine; Cyclophosphamide; Disease-Free Survival; Drug Synergism; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lenograstim; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Retrospective Studies; Serum Albumin; Transplantation Conditioning; Transplantation, Autologous | 2009 |
Chemomobilization with Etoposide is Highly Effective in Patients with Multiple Myeloma and Overcomes the Effects of Age and Prior Therapy.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Blood Component Removal; Cell Count; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Transplantation, Autologous | 2011 |
EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Prednisone; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Vincristine | 2011 |
Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Rituximab; Transplantation, Autologous; Young Adult | 2011 |
Retrospective analysis of an efficient peripheral blood stem cell collection and the relation between infused cell dose and clinical outcome in patients with malignant lymphoma and multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Specimen Collection; Drug Dosage Calculations; Etoposide; Female; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Survival Analysis; Treatment Outcome | 2012 |
Dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide (DPACE) is an effective salvage regimen for multiple myeloma refractory to novel agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Humans; Multiple Myeloma; Salvage Therapy; Treatment Outcome | 2013 |
Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cell Division; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease Progression; Doxorubicin; Etoposide; Fatal Outcome; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Neoplastic Stem Cells; Peripheral Blood Stem Cell Transplantation; Thalidomide; Vincristine | 2002 |
A combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; Etoposide; Female; Flow Cytometry; Humans; Leukocytes; Male; Middle Aged; Multiple Myeloma; Stem Cells; Time Factors | 2002 |
Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Immunosuppression Therapy; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Platelet Count; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Time Factors; Transplantation, Autologous; Whole-Body Irradiation | 2003 |
Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Humans; Multiple Myeloma; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Venous Thrombosis; Vincristine | 2003 |
Thalidomide: new indication. A last resort in myeloma.
Topics: Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Drug Approval; Drug Therapy, Combination; Etoposide; Female; France; Humans; Interferon alpha-2; Interferon-alpha; Male; Multiple Myeloma; Recombinant Proteins; Thalidomide | 2003 |
[Orbital extension of sinus plasmacytoma secondarily transforming into multiple myeloma: a case study].
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Dexamethasone; Diplopia; Doxorubicin; Ethmoid Sinus; Etoposide; Exophthalmos; Humans; Male; Maxillary Sinus; Maxillary Sinus Neoplasms; Methylprednisolone Hemisuccinate; Multiple Myeloma; Orbit; Orbital Neoplasms; Paranasal Sinus Neoplasms; Plasmacytoma; Tomography, X-Ray Computed; Treatment Outcome; Vincristine; Visual Acuity | 2004 |
Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Etoposide; Female; Follow-Up Studies; Graft Survival; Hematopoiesis; Humans; Idarubicin; Ifosfamide; Infections; Male; Middle Aged; Multiple Myeloma; Neutropenia; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine; Whole-Body Irradiation | 2004 |
The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Blotting, Western; Cell Line, Tumor; Cell Nucleus; Comet Assay; Cytoplasm; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Etoposide; Fatty Acids, Unsaturated; Flow Cytometry; HL-60 Cells; Humans; Microscopy, Fluorescence; Mitoxantrone; Multiple Myeloma; Plasmacytoma; Protein Transport; Subcellular Fractions | 2004 |
Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Cisplatin; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Male; Methylprednisolone; Middle Aged; Multiple Myeloma; Plasma Cells | 2004 |
Salvage therapy options for myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Doxorubicin; Etoposide; Glucocorticoids; Humans; Immunosuppressive Agents; Male; Multiple Myeloma; Plasmapheresis; Radiotherapy, Adjuvant; Salvage Therapy; Spine; Thalidomide | 2004 |
[Economic impact of outpatient chemotherapy in multiple myeloma].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Female; France; Hospital Costs; Hospitalization; Humans; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Sensitivity and Specificity | 2004 |
Hemophagocytic lymphohistiocytosis after chemotherapy for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Marrow; Cyclosporine; Dexamethasone; Etoposide; Histiocytosis, Non-Langerhans-Cell; Humans; Male; Middle Aged; Multiple Myeloma; Treatment Outcome | 2004 |
Nephrotic syndrome in patients with peripheral blood stem cell transplant.
Topics: Acute Kidney Injury; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytomegalovirus Infections; Etoposide; Glomerulonephritis, Membranous; Graft vs Host Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Multiple Myeloma; Nephrotic Syndrome; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Prednisone; Rituximab; Sepsis; Staphylococcal Infections; Tacrolimus; Transplantation Conditioning | 2005 |
Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.
Topics: Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Farnesyltranstransferase; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Melphalan; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Phenotype; Protease Inhibitors; Protein Prenylation; Pyrazines; Quinolones; ras Proteins; Staurosporine; Tunicamycin | 2005 |
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Epirubicin; Etoposide; Female; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mitoxantrone; Multiple Myeloma; Odds Ratio; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Recurrence; Remission Induction; Salvage Therapy; Time Factors; Transplantation Conditioning; Treatment Outcome | 2005 |
Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2006 |
Comparison of peripheral blood progenitor cell yield from standard chemotherapy used in the treatment of lymphoid malignancies and high-dose cyclophosphamide: a retrospective review of 141 patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Retrospective Studies | 2006 |
Thalidomide for the treatment of leptomeningeal multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Fatal Outcome; Female; Humans; Immunoglobulin G; Melphalan; Meningeal Neoplasms; Middle Aged; Multiple Myeloma; Nitrosourea Compounds; Prednisolone; Prednisone; Thalidomide; Vindesine | 2006 |
New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Korea; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Blood Stem Cell Transplantation; Predictive Value of Tests; Remission Induction; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2006 |
VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Etoposide; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Protease Inhibitors; Pyrazines; Remission Induction | 2006 |
High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Survival Rate; Transplantation, Autologous | 2007 |
Four-color flow cytometric analysis of myeloma plasma cells.
Topics: Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Cells; Combined Modality Therapy; Dexamethasone; Doxorubicin; Etoposide; Female; Flow Cytometry; Humans; Immunophenotyping; Male; Melphalan; Middle Aged; Multiple Myeloma; Staining and Labeling; Stem Cell Transplantation; Vincristine | 2006 |
[Pulmonary and pleural manifestations of multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Humans; Immunoglobulin G; Immunoglobulin lambda-Chains; Lung; Lung Neoplasms; Male; Multiple Myeloma; Plasma Cells; Pleura; Pleural Effusion, Malignant; Pleural Neoplasms; Prednisone; Vincristine | 2006 |
Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalan.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carmustine; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Infusions, Intravenous; Male; Melphalan; Mexico; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation, Autologous; Treatment Outcome | 2007 |
Ifosfamide, epirubicin, and etoposide (IEV) mobilize peripheral blood stem cells more efficiently than cyclophosphamide/etoposide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation, Autologous; Treatment Outcome | 2007 |
[Nutritional pathway for autologous stem cell transplantation].
Topics: Antineoplastic Agents, Alkylating; Body Weight; Carboplatin; Critical Pathways; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Melphalan; Multiple Myeloma; Parenteral Nutrition, Total; Transplantation Conditioning; Transplantation, Autologous | 2007 |
[Treatment and survival of multiple myeloma patients on programmed hemodialysis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Kidney Failure, Chronic; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Renal Dialysis; Retrospective Studies; Survival Rate; Treatment Outcome | 2007 |
[Comparison of regimen-related toxicity between high-dose melphalan and ICE as a preparatory regimen for autologous stem cell transplantation].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Humans; Ifosfamide; Lymphoma; Male; Melphalan; Middle Aged; Multiple Myeloma; Stem Cell Transplantation; Transplantation, Autologous | 2007 |
Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Europe; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Lymphoma, Non-Hodgkin; Male; Medical Audit; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Prospective Studies; Research Design; Risk Assessment; Risk Factors; Stomatitis; Transplantation Conditioning; Transplantation, Autologous | 2008 |
Visual hallucinations following treatment with vincristine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cyclophosphamide; Doxorubicin; Etoposide; Hallucinations; Humans; Lymphoma, T-Cell; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Prednisolone; Prednisone; Procarbazine; Salvage Therapy; Serotonin; Structure-Activity Relationship; Vincristine | 1994 |
Etoposide, dexamethasone, and continuous-infusion cyclophosphamide with G-CSF for VAD-resistant multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Resistance; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Vincristine | 1995 |
[Secondary myeloid/natural killer cell acute leukemia appeared in multiple myeloma treated with melphalan].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Etoposide; Fatal Outcome; Female; Humans; Killer Cells, Natural; Leukemia, Myeloid, Acute; Melphalan; Multiple Myeloma; Neoplasms, Second Primary; Prednisolone | 1995 |
The effect of anticancer drug sequence in experimental combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Survival; Cisplatin; Drug Administration Schedule; Endometrial Neoplasms; Etoposide; Female; Humans; Kinetics; Mitomycin; Multiple Myeloma; Tumor Cells, Cultured | 1993 |
[Peripheral blood stem cell transplantation in adult patients].
Topics: Adolescent; Adult; Blood Cell Count; Cell Separation; Chemotherapy, Adjuvant; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Middle Aged; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1993 |
Role of chemotherapy and GM-CSF on hemopoietic progenitor cell mobilization in multiple myeloma.
Topics: Adult; Aged; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Colony-Forming Units Assay; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Feasibility Studies; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Immunologic Factors; Lymphoma; Male; Middle Aged; Multiple Myeloma; Pilot Projects; Prednisone; Recombinant Proteins; Vincristine | 1993 |
Interleukin-6 inhibits apoptosis of malignant plasma cells.
Topics: Apoptosis; Cell Line; Dactinomycin; Dexamethasone; DNA Damage; Doxorubicin; Etoposide; Humans; In Vitro Techniques; Interleukin-6; Multiple Myeloma; Plasma Cells; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2 | 1995 |
Quality and functional capacity of the bone marrow microenvironment of autologous blood stem cell transplantation (ABSCT) recipients.
Topics: Bone Marrow; Carmustine; Cells, Cultured; Colony-Forming Units Assay; Connective Tissue; Cyclophosphamide; Cytarabine; Etoposide; Graft Survival; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Multiple Myeloma; Transplantation, Autologous; Whole-Body Irradiation | 1994 |
Early myeloablative therapy for multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Resistance; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Life Tables; Melphalan; Middle Aged; Multiple Myeloma; Radiation Injuries; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Thiotepa; Treatment Outcome; Vincristine; Whole-Body Irradiation | 1994 |
Amendment to clinical research projects. Genetic marking with retroviral vectors to study the feasibility of stem cell gene transfer and the biology of hematopoietic reconstitution after autologous transplantation in multiple myeloma, chronic myelogenous
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Breast Neoplasms; Cisplatin; Clinical Protocols; Combined Modality Therapy; Cyclophosphamide; Etoposide; Feasibility Studies; Genetic Therapy; Genetic Vectors; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melphalan; Multiple Myeloma; Neoplasm Metastasis; Retroviridae; Transfection; Transplantation, Autologous; Whole-Body Irradiation | 1993 |
[A case of refractory multiple myeloma effectively treated with long-term oral etoposide].
Topics: Administration, Oral; Etoposide; Humans; Immunoglobulin gamma-Chains; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Remission Induction | 1993 |
Solitary plasmacytoma of bone--a rare disorder with an unusual evolution.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Liver Neoplasms; Multiple Myeloma; Plasmacytoma; Spinal Neoplasms; Splenectomy; Splenic Neoplasms; Vincristine | 1993 |
Both early and committed haemopoietic progenitors are more frequent in peripheral blood than in bone marrow during mobilization induced by high-dose chemotherapy + G-CSF.
Topics: Adult; Bone Marrow; Colony-Forming Units Assay; Cyclophosphamide; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Phenotype | 1995 |
Oral low-dose etoposide therapy for refractory multiple myeloma with extramedullary involvement.
Topics: Administration, Oral; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Humans; Male; Multiple Myeloma; Prednisolone; Procarbazine; Remission Induction | 1995 |
High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose-toxicity study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Liver Function Tests; Lymphoma; Male; Melphalan; Middle Aged; Multiple Myeloma; Respiratory Function Tests; Retrospective Studies; Transplantation, Autologous | 1996 |
Kaposi's sarcoma after autologous bone marrow transplantation for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Etoposide; Fatal Outcome; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Immunocompromised Host; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recombinant Proteins; Sarcoma, Kaposi; Skin Neoplasms; Transplantation, Autologous | 1996 |
Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Culture Media, Serum-Free; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; fas Receptor; Gene Expression Regulation, Neoplastic; Humans; Hydrogen Peroxide; Molecular Sequence Data; Multiple Myeloma; Neoplasm Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 1996 |
A comparison of a CB17 scid mouse model and the tetrazolium-dye assay using human haematological tumour cell lines.
Topics: Animals; Antineoplastic Agents; Burkitt Lymphoma; Coloring Agents; Daunorubicin; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Idarubicin; Leukemia, Experimental; Male; Mice; Mice, SCID; Multiple Myeloma; Tetrazolium Salts; Toxicity Tests; Tumor Cells, Cultured | 1996 |
Higher in vivo protein binding of etoposide in children compared with adult cancer patients.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Child; Child, Preschool; Etoposide; Female; Histiocytic Sarcoma; Humans; Infant; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma; Male; Middle Aged; Multiple Myeloma; Oligodendroglioma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Binding; Reference Values; Serum Albumin | 1996 |
High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Transplantation Conditioning; Whole-Body Irradiation | 1996 |
Parkinsonian syndrome in a dialysis-supported patient receiving high-dose chemotherapy for multiple myeloma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Hemofiltration; Humans; Immunoglobulin kappa-Chains; Male; Middle Aged; Multiple Myeloma; Parkinson Disease, Secondary; Renal Insufficiency | 1997 |
Intermittent exposure to doxorubicin in vitro selects for multifactorial non-P-glycoprotein-associated multidrug resistance in RPMI 8226 human myeloma cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Doxorubicin; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Humans; Multiple Myeloma; Tumor Cells, Cultured; Verapamil; Vincristine | 1997 |
Sodium and potassium excretion changes and bone marrow recovery after chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carcinoma, Small Cell; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Multiple Myeloma; Potassium; Sodium | 1999 |
Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy.
Topics: Adult; Ambulatory Care; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Diphenhydramine; Etoposide; Evaluation Studies as Topic; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Infusion Pumps; Infusions, Intravenous; Lorazepam; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Nausea; Patient Acceptance of Health Care; Prospective Studies; Safety; Self Care; Thiotepa; Vomiting | 1999 |
Cell density-dependent VP-16 sensitivity of leukaemic cells is accompanied by the translocation of topoisomerase IIalpha from the nucleus to the cytoplasm.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Cell Nucleus; Cytoplasm; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Etoposide; Flow Cytometry; Humans; Leukemia; Multiple Myeloma; Phenotype; Translocation, Genetic; Tumor Cells, Cultured | 2000 |
Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation.
Topics: Adjuvants, Immunologic; Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Filgrastim; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Lenograstim; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Recombinant Proteins; Time Factors; Transplantation, Autologous; Vincristine | 2000 |
Clonal variability in CD95 expression is the major determinant in Fas-medicated, but not chemotherapy-medicated apoptosis in the RPMI 8226 multiple myeloma cell line.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 8; Caspase 9; Caspases; Cell Survival; Clone Cells; Doxorubicin; Etoposide; fas Receptor; Flow Cytometry; Humans; Multiple Myeloma; Transcription, Genetic; Tumor Cells, Cultured; Vincristine | 2000 |
[Complete remission of plasmablastic IgD lambda multiple myeloma induced by continuous infusion of low-dose cytarabine and etoposide].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Infusions, Intravenous; Male; Multiple Myeloma; Remission Induction; Treatment Outcome | 2000 |
A case of aggressive multiple myeloma with cleaved, multilobated, and monocytoid nuclei, and no serum monoclonal gammopathy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cell Cycle; Cisplatin; Cyclophosphamide; Dexamethasone; Etoposide; Flow Cytometry; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Leukemia, Plasma Cell; Male; Multiple Myeloma; Neoplasms, Second Primary; Prognosis; Thalidomide | 2000 |
Cellular biological differences between human myeloma cell lines KMS-12-PE and KMS-12-BM established from a single patient.
Topics: Antigens, Surface; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Blotting, Western; Bone Marrow; Cell Division; Clone Cells; Etoposide; Female; Humans; Immunophenotyping; Interferon-gamma; Interleukin-6; Japan; Melphalan; Middle Aged; Multiple Myeloma; Pleural Effusion; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2000 |
Radiation-associated pneumonitis following autologous stem cell transplantation: predictive factors, disease characteristics and treatment outcomes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Predictive Value of Tests; Prognosis; Radiation Pneumonitis; Retrospective Studies; Transplantation, Autologous; Whole-Body Irradiation | 2001 |
Aggressive neoplastic plasma cell growth with MLL gene rearrangement after high-dose therapy with autologous stem cell support for multiple myeloma.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cytogenetic Analysis; Etoposide; Female; Gene Rearrangement; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Plasma Cells; Recurrence; Transplantation, Autologous | 2001 |
Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lung Diseases, Fungal; Male; Middle Aged; Multiple Myeloma; Pneumonia, Pneumocystis; Syndrome; Transplantation Conditioning | 2001 |
Trafficking of CD34+ cells into the peripheral circulation during collection of peripheral blood stem cells by apheresis.
Topics: Acute Disease; Adult; Antigens, CD34; Blood Cell Count; Blood Component Removal; Blood Platelets; Cyclophosphamide; Dexamethasone; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Granulocytes; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid; Male; Middle Aged; Monocytes; Multiple Myeloma; Paclitaxel; Prospective Studies; Recombinant Proteins; Transplantation, Autologous | 2001 |
37th Annual American Society of Clinical Oncology Meeting. San Francisco, CA. May 12-15, 2001.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Adhesion Molecules; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Immunosuppressive Agents; Immunotoxins; Lectins; Leukemia, Hairy Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Rituximab; Sialic Acid Binding Ig-like Lectin 2; Thalidomide; Vinblastine | 2001 |
Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Multiple Myeloma; Prognosis; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Thalidomide | 2001 |
Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Cell Survival; DNA Fragmentation; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Flow Cytometry; Humans; Kinetics; Membrane Glycoproteins; Multiple Myeloma; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2001 |
DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow Purging; Cisplatin; Cyclophosphamide; Dexamethasone; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Male; Middle Aged; Multiple Myeloma; Treatment Outcome | 2001 |
Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients.
Topics: Adult; Ambulatory Care; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematologic Diseases; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Recombinant Proteins | 1992 |
High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support for refractory multiple myeloma.
Topics: Blood Transfusion, Autologous; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Middle Aged; Multiple Myeloma; Transplantation, Autologous | 1990 |
Purging of myeloma cells from bone marrow using monoclonal antibodies and magnetic immunobeads in combination with 4-hydroperoxycyclophosphamide.
Topics: Antibodies, Monoclonal; Antigens, Neoplasm; Bone Marrow; Bone Marrow Cells; Colony-Forming Units Assay; Combined Modality Therapy; Cyclophosphamide; Etoposide; Humans; Magnetics; Microspheres; Multiple Myeloma; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1990 |
Diagnosis and treatment of high-grade myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Etoposide; Humans; L-Lactate Dehydrogenase; Multiple Myeloma | 1990 |
Treatment of multiple myeloma by high dose chemotherapy, total body irradiation and autologous blood stem cell autograft.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Etoposide; Evaluation Studies as Topic; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Remission Induction; Transplantation, Autologous; Whole-Body Irradiation | 1989 |
Ex vivo treatment of myeloma cells by 4-HC, VP-16, LAK cells and antibodies.
Topics: Antibodies, Monoclonal; Cell Separation; Colony-Forming Units Assay; Cyclophosphamide; Cytotoxicity, Immunologic; Etoposide; Hematopoietic Stem Cells; Humans; Killer Cells, Natural; Magnetics; Multiple Myeloma; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1989 |
Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Doxorubicin; Drug Resistance; Etoposide; Humans; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisone; Vincristine | 1989 |
Resistant multiple myeloma treated with mitozantrone in combination with vincristine and dexamethasone (MOD)
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dexamethasone; Doxorubicin; Drug Administration Schedule; Drug Resistance; Etoposide; Humans; Immunoglobulin G; Middle Aged; Mitoxantrone; Multiple Myeloma; Vincristine | 1989 |
Modulation of etoposide cytotoxicity and DNA strand scission in L1210 and 8226 cells by polyamines.
Topics: Animals; Cell Survival; DNA Topoisomerases, Type II; DNA, Neoplasm; DNA, Single-Stranded; Eflornithine; Etoposide; Humans; Leukemia L1210; Mice; Multiple Myeloma; Nucleic Acid Conformation; Ornithine; Podophyllotoxin; Polyamines; Putrescine | 1986 |